CD133-specific CAR-T cells were shown to kill GSCs and slightly prolong the survival of glioma-bearing mice [49], while GD2-specific CAR-T cells can prolong survival in glioma nerve stem cell-derived tumor-bearing mice [50]. This evidence concerns the gene PROM1 and central nervous system cancer.